scholarly journals Breast cancer in Egypt:a review of disease presentation and detection strategies

2021 ◽  
Vol 9 (3) ◽  
pp. 448-463
Author(s):  
S. Omar ◽  
H. Khaled ◽  
R. Gaafar ◽  
A. R. Zekry ◽  
S. Eissa ◽  
...  
Keyword(s):  
Hormone Receptors ◽  
Prognostic Markers ◽  
Locally Advanced ◽  
Progesterone Receptors ◽  
Carcinoma Of The Breast ◽  
Genetic Changes ◽  
Egyptian Women ◽  
Disease Stages ◽  
Detection Strategies ◽  
Results Of Surgery

Carcinoma of the breast is the most prevalent cancer among Egyptian women and constitutes 29% of National Cancer Institute cases. Median age at diagnosis is one decade younger than in countries of Europe and North America and most patients are premenopausal. Tumours are relatively advanced at presentation. The majority of tumours are invasive duct subtype and the profile of hormone receptors is positive for estrogen receptors and /or progesterone receptors in less than half of cases. This overview examines genetic changes, potential and established predictive and prognostic markers and end results of surgery, radiotherapy and systemic therapy for early, locally advanced and metastatic disease stages. Disease presentations common to the region and early detection strategies are presented

scholarly journals Y-Box binding protein 1 expression in breast cancer and its correlation with hormone receptors and other prognostic markers

2018 ◽  
Vol 10 (04) ◽  
pp. 420-425 ◽  
Author(s):  
Taruna Bansal ◽  
Nadeem Tanveer ◽  
Usha Rani Singh ◽  
Sonal Sharma ◽  
Navneet Kaur
Keyword(s):  
Breast Carcinoma ◽  
Hormone Receptors ◽  
Prognostic Markers ◽  
Binding Protein ◽  
Radical Mastectomy ◽  
Positive Association ◽  
Tumor Stage ◽  
Lymph Node Involvement ◽  
Clinical Parameters ◽  
Node Involvement

Abstract INTRODUCTION: The present histologic and immunohistochemical prognostic markers of breast carcinoma do not effectively identify the subset of patients with poor prognosis. Y-Box binding protein 1 (YB1) is a novel biomarker which may identify and aid in targeted personalized therapy for such patients. MATERIALS AND METHODS: The study was conducted on histopathology specimens of 74 patients of breast carcinoma who had undergone modified radical mastectomy. YB1 immunohistochemistry (IHC) was performed on manual tissue microarray blocks (each having 15 cores). The YB1 expression was quantified in terms of “immunoreactive score” which was correlated with clinical parameters, hormone receptor status, and Her2neu overexpression by IHC. The Her2neu status of the equivocal cases was further evaluated by fluorescent in situ hybridization (FISH). RESULTS: YB1 was positive in 36/74 (48.6%) cases. On IHC and analysis by FISH, 25/74 (34%) cases had Her2neu overexpression. Estrogen receptor (ER) and progesterone receptor (PR) positivity was found in 42% and 36.5% cases, respectively. YB1 immunopositivity was negatively correlated with ER and PR expression, but showed a significant positive correlation with Her2neu expression. No correlation was found with other clinical parameters, tumor stage, and grade, except lymph node involvement, which showed a positive association with YB1 expression. Triple-negative breast carcinoma constituted 25.6% of the total cases, out of which 73.6% were YB1 positive. CONCLUSION: This study found that YB1 has an association with Her2neu expression. It may in future provide a therapeutic target in Her2neu overexpressing tumors.

Neo-Adjuvant chemotherapy in 100 patients with locally advanced carcinoma of the breast

1994 ◽  
pp. 120-122
Author(s):  
B. Coudert ◽  
P. Gabez ◽  
C. Lamaille ◽  
C. De Gislain ◽  
F. Mayer ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Locally Advanced ◽  
Carcinoma Of The Breast ◽  
Advanced Carcinoma ◽  
Neo Adjuvant Chemotherapy

scholarly journals Hormone receptors in hepatoblastoma: A demonstration of both estrogen and progesterone receptors

Cancer ◽  
1982 ◽  
Vol 50 (9) ◽  
pp. 1828-1832 ◽  
Author(s):  
D. Jeffrey Demanes ◽  
Michael A. Friedman ◽  
James H. McKerrow ◽  
Philip G. Hoffman
Keyword(s):  
Hormone Receptors ◽  
Progesterone Receptors ◽  
Estrogen And Progesterone Receptors

External and Interstitial Radiation Therapy of Locally Advanced Carcinoma of the Breast

1992 ◽  
Vol 31 (3) ◽  
pp. 303-306 ◽  
Author(s):  
Fernand Guedea ◽  
Albert Biete ◽  
Jordi Craven-Bartle ◽  
Carmen Alonso ◽  
BelÉN Ojeda
Keyword(s):  
Radiation Therapy ◽  
Locally Advanced ◽  
Carcinoma Of The Breast ◽  
Advanced Carcinoma ◽  
Interstitial Radiation Therapy ◽  
Interstitial Radiation

Squamous Cell Carcinoma of the Breast: A Review of 177 Cases

2009 ◽  
Vol 75 (10) ◽  
pp. 914-917 ◽  
Author(s):  
Julia Grabowski ◽  
Sidney L. Saltzstein ◽  
Georgia Sadler ◽  
Sarah Blair
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Regional Lymph Node ◽  
Locally Advanced ◽  
Carcinoma Of The Breast ◽  
Cumulative Survival ◽  
Time Period ◽  
California Cancer Registry ◽  
Long Term Prognosis

Squamous cell carcinoma (SCO of the breast is an uncommon breast neoplasm. There are limited data about its epidemiology and few studies focusing on outcomes. This study aims to identify specific characteristics of patients with breast SCC, investigate its natural history, and determine its long-term prognosis. One hundred and seventy-seven cases of SCC of the breast were identified in the California Cancer Registry from the years 1988 to 2006. At the time of diagnosis, 53 per cent of patients had localized disease, 32 per cent of patients had regional lymph node or locally advanced disease, and 8 per cent of patients had distant disease. The relative cumulative survival of patients was 68.1 per cent at 5 years and 60.2 per cent at 10 years. This is significantly worse than the relative cumulative survival of patients with all other invasive breast tumors during the same time period. Squamous cell carcinoma of the breast is a rare and aggressive disease, and it has significantly worse prognosis than other nonsquamous cell tumors of the breast. Clinicians should be aware of the aggressive nature of the tumor when counseling patients.

scholarly journals Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast

Cancer ◽  
2002 ◽  
Vol 94 (4) ◽  
pp. 895-901 ◽  
Author(s):  
Andrea de Matteis ◽  
Francesco Nuzzo ◽  
Giuseppe D'Aiuto ◽  
Vincenzo Labonia ◽  
Gabriella Landi ◽  
...  
Keyword(s):  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Carcinoma Of The Breast ◽  
Advanced Carcinoma

scholarly journals The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers

2005 ◽  
Vol 12 (3) ◽  
pp. 511-532 ◽  
Author(s):  
K-M Rau ◽  
H-Y Kang ◽  
T-L Cha ◽  
S A Miller ◽  
M-C Hung
Keyword(s):  
Hormone Receptors ◽  
Locally Advanced ◽  
Endocrine System ◽  
Therapy Resistance ◽  
The United States ◽  
Breast And Prostate Cancer ◽  
Prostate Cancers ◽  
Locally Advanced Tumors ◽  
Underlying Mechanisms ◽  
Clinical Potential

Breast and prostate cancer are the most well-characterized cancers of the type that have their development and growth controlled by the endocrine system. These cancers are the leading causes of cancer death in women and men, respectively, in the United States. Being hormone-dependent tumors, antihormone therapies usually are effective in prevention and treatment. However, the emergence of resistance is common, especially for locally advanced tumors and metastatic tumors, in which case resistance is predictable. The phenotypes of these resistant tumors include receptorpositive, ligand-dependent; receptor-positive, ligand-independent; and receptor-negative, ligand-independent. The underlying mechanisms of these phenotypes are complicated, involving not only sex hormones and sex hormone receptors, but also several growth factors and growth factor receptors, with different signaling pathways existing alone or together, and with each pathway possibly linking to one another. In this review, we will discuss the potential mechanisms of antihormonetherapy resistance in breast and prostate cancers, especially focusing on the similarities and differences of these two cancers. We will also discuss novel agents that have been applied in clinical practice or with clinical potential in the future.

Molecular Genetics in the Diagnosis and Prognosis of Solid Pediatric Tumors

1998 ◽  
Vol 1 (5) ◽  
pp. 337-365 ◽  
Author(s):  
Paul S. Thorner ◽  
Jeremy A. Squire
Keyword(s):  
Molecular Genetics ◽  
Fusion Proteins ◽  
Tumor Suppressor Genes ◽  
Prognostic Markers ◽  
Wilms Tumor ◽  
Pediatric Tumors ◽  
Peripheral Primitive Neuroectodermal Tumor ◽  
Genetic Changes ◽  
Pediatric Tumor ◽  
Diagnosis And Prognosis

The field of molecular genetics continues to see an ever increasing number of applications to pediatric tumor analysis. Studies in pediatric tumors have identified novel genes and other genetic changes, a large number of which reflect one of the following mechanisms: ( 1) activation of proto-oncogenes; ( 2) loss of tumor suppressor genes; or ( 3) creation of novel fusion proteins. At least one of these mechanisms is operational in each of the following pediatric tumors: neuroblastoma, Ewing sarcoma and peripheral primitive neuroectodermal tumor (pPNET), intra-abdominal desmoplastic small-cell tumor, rhabdomyosarcoma, synovial sarcoma, and Wilms tumor. Out of this research has come not only an increased understanding of oncogenesis but also, for each of the tumors listed above, diagnostic and/or prognostic markers that can be used by the pathologist and oncologist to improve overall patient management.

Sign in / Sign up

Export Citation Format

Share Document